‘Advocating for a treatment, but denied access to it’
July 17th, 2008From the New York Times:
A lawsuit recently filed in federal court exposes the increasingly blurry boundary between medical research and treatments that patients and their families hope will save lives. Cheri Gunvalson of Minnesota is suing a biotechnology company for access to an experimental drug she says could help her 16-year-old son, who has Duchenne muscular dystrophy.
She claims that she advocated on behalf of PTC Therapeutics, and that executives of the company repeatedly assured her that her son would get the drug. The company denies making such promises and says her son does not qualify for clinical trials.
Ms. Gunvalson is being represented by one of Minnesota’s most prominent lawyers, Michael A. Hatch, the former state attorney general.
This entry was posted
on Thursday, July 17th, 2008 at 8:56 am and is filed under law, muscular dystrophy, research news.
You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.
Email This Post
Our RSS Feed